0000905718-20-000795.txt : 20200731 0000905718-20-000795.hdr.sgml : 20200731 20200731122601 ACCESSION NUMBER: 0000905718-20-000795 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200731 DATE AS OF CHANGE: 20200731 EFFECTIVENESS DATE: 20200731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AzurRx BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-372224 FILM NUMBER: 201064780 BUSINESS ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 BUSINESS PHONE: 646-699-7855 MAIL ADDRESS: STREET 1: 760 PARKSIDE AVENUE STREET 2: SUITE 304 CITY: BROOKLYN STATE: NY ZIP: 11226 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 D 1 primary_doc.xml X0708 D LIVE 0001604191 AzurRx BioPharma, Inc. 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY NEW YORK 11226 646-699-7855 DELAWARE None BioPharma d'Azur, Inc. Corporation true Daniel Schneiderman 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Gregory Oakes 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director Edward Borkowski 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director Alastair Riddell 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director James Sapirstein 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Director Charles Casamento 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director Vern Lee Schramm 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Director James Lee Pennington 760 Parkside Ave. Suite 304 Brooklyn NY NEW YORK 11226 Executive Officer Biotechnology Decline to Disclose 06b false 2020-07-16 false true true true false 0 Alexander Capital, L.P. 40077 None None 17 STATE STREET 5TH FLOOR NEW YORK NY NEW YORK 10004 All States false 22800000 22426890 373110 Includes the conversion of certain indebtedness false 177 1350000 true 0 Alexander Capital, L.P. also received a 1% non-accountable expense allowance and a 3% advisory fee, or approximately $300,000 in aggregate, and was issued warrants exercisable for 1,382,902 shares of common stock, at an exercise price of $1.06 per share. 0 true Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. false AzurRx BioPharma, Inc. /s/ Daniel Schneiderman Daniel Schneiderman Chief Financial Officer 2020-07-31